Translational Research & Strategic Services
Kinexum guides, designs, and manages strategic and operational solutions to the regulatory, manufacturing, nonclinical, clinical development, and business challenges necessary to take scientific discoveries to proof of concept and through the product life cycle.
Kinexum teams supplement the strengths of large and small organizations to reach high-value milestones effectively and efficiently. Kinexum specializes in crafting creative but sound and integrated solutions across scientific disciplines, therapeutic areas, product modalities, and business stages. We respond to emergencies and as well as requests for problem prevention and complex long-range planning.
News and Upcoming events
Kinexum next Public Webinar will be on Friday, 07/13/2018, at 11 am EDT to noon:
"European Medicine Agency - Some Recent & Anticipated Changes"
Presenter: Dr. Bart Van der Schueren, IG Endocrinoligie UZ Leuzen, Belgian Representative on EMA
Click here to see invitation
Please log in or dial 888-601-3595
Our Charles Alexander will be attending the 2nd Annual Heart in diabetes (HiD) Medical Conference in Philadelphia from Friday 07/13/2018 till Sunday 07/15/2018.
Blazing Clinical Development & Regulatory Pathways for Healthspan Interventions - Dr. Fleming presents at the Nathan Shock Centers Summit & American Aging Association 47th Annual Meeting, June 27th, 2018, Philadelphia, PA
Kinexum Public Webinar is on Friday, 06/08/2018, at 11 am ET to noon:
Rob Claar of HekaBio KK will Present:
Fast Track Cell Therapy Opportunities Under Japanese Regulations
Click here to see presentation on Youtube
Special Webcast interview is now available on audio
Dr. Lawrence Steinman: From Big Hammers to Lasers:
Lessons learned in targeting the immune system to reverse or prevent disease
Interviewed by Dr. Alexander Fleming
Kinexum Public Webinar from Friday, 04/27/2018, is now available on audio (please start at minute 11):
David Fox and Phil Katz of Hogan Lovells will present -
Regulatory Outlook under FDA Commissioner Scott Gottlieb and DHH Secretary Alex Azar
Click here to see the invitation
|
Kinexum executives and leading expert will attend the conferences in this section. Anyone interested in meeting them, please contact This email address is being protected from spambots. You need JavaScript enabled to view it. . |
Recent Articles
Beyond Hemoglobin A1C Consensus Conference - July 21, 2017 Charles M. Alexander, MD
Originally, diabetes was a symptomatic condition with either diabetic ketoacidosis (DKA) in type 1 diabetes or marked weight loss, muscle wasting, and inanition in type 2 diabetes. Prognosis was dismal for both and the main difference was the rapidity of the patient’s demise.
Beyond Hemoglobin A1C Consensus Conference - July 21, 2017 - Full Article
Early on Commercial Planning Investments within the R&D Process: The Business Case - Martin Lafontaine
Commercial investments within the early phase of R&D generally rank very low on a company’s priority list. To use a sports expression, commercial investments often don’t make the cut, and get relegated to the bench.
Early on Commercial Planning Investments within the R&D Process: The Business Case - Full Article
Marketing Added Value - Arthur Santora MD, Ph.D
Fosamax was the first treatment for osteoporosis in postmenopausal women approved based phase 3 data demonstrating a reduction in the incidence of vertebral fractures. Marketing Added Value - Full Article
Privacy Policy
You may visit the Kinexum web site without telling us who you are or revealing any information about yourself. Our servers collect the domain names, not the e-mail addresses, of those who visit our site. Kinexum uses this information to measure the use and effectiveness of our site and to improve its content.
If there are times when we may need specific information from you, we will let you know at the time of collection how we will use the personal information. Examples of these times are: you have asked for a response to an inquiry or you want to gain access to specific information. You will be offered an opportunity to limit access to your information, should we be asked to make it available to other organizations.
